In Vitro and In Vivo Data Show Alfacell’s ONCONASE(R) is Active Against Naive and Chemoresistant Neuroblastoma Cells
Source: Alfacell Corporation
Alfacell has announced more pre-clinical successes for ONCOCASE, it’s leading drug candidate. The latest results, published in the journal Cancer Letters, show that ONCONASE “inhibits neuroblastoma cell growth and induces caspase-independent cell death in neuroblastoma cells independently of P-gp expression or p53 status….” Neuroblastoma is a cancer that forms in the nerve tissue. It is the most common type of cancer in infants and the fourth most common type to affect children in general.
The success of these tests follow shortly after Alfacell’s announcement in May that ONCOCASE shows promise as a chemopreventive agent for the treatment of mesothelioma. In that announcement, Alfacell noted that Dr. Michele Carbone, one of the world’s leading mesothelioma researchers, discovered that ONCONASE triggers apoptosis in mesothelioma cells and that it blocks the molecular pathway that causes asbestos carcinogenesis.
These latest results show even greater promise for the use of ONCONASE as a cancer-fighting agent.